Characteristics of patients diagnosed with a haematological malignancy (HM) and systemic lupus erythematosus (SLE) concurrently*
| ANA | 7/7 | (100%) |
| dsDNA Ab | 5/7 | (71%) |
| Phospholipid Ab | 2/7 | (29%) |
| Arthritis | 7/7 | (100%) |
| Haematological | 5/7 | (71%) |
| Nephritis | 0/7 | (0%) |
| Plaquenil (SLE) | 6/7 | (86%) |
| Methotrexate (SLE) | 1/7 | (14%) |
| Chemotherapy (HM) | 5/7 | (71%) |
*The two diagnoses were made within 1 year of each other (mean, 4 months).
Ab, antibody; ANA, antinuclear antibody; dsDNA, double-stranded DNA.